Sotera Health (NASDAQ:SHC) Receives $15.80 Consensus Price Target from Brokerages

Sotera Health (NASDAQ:SHC) has been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $15.80.

SHC has been the topic of several recent analyst reports. Piper Sandler lowered their price target on Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, April 23rd. Barclays lowered their price target on Sotera Health from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Wall Street Zen cut Sotera Health from a “buy” rating to a “hold” rating in a report on Saturday, June 7th. Finally, The Goldman Sachs Group raised Sotera Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $14.00 to $17.00 in a report on Monday, May 5th.

Sotera Health Stock Down 2.0%

Shares of NASDAQ SHC opened at $12.06 on Friday. Sotera Health has a 52 week low of $9.53 and a 52 week high of $17.08. The business has a 50-day simple moving average of $11.82 and a two-hundred day simple moving average of $12.54. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The company has a market cap of $3.42 billion, a P/E ratio of 48.24 and a beta of 1.87.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.02. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The firm had revenue of $254.52 million for the quarter, compared to analysts’ expectations of $245.56 million. During the same quarter last year, the firm posted $0.13 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Research analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sotera Health

A number of large investors have recently modified their holdings of SHC. TPG GP A LLC purchased a new position in shares of Sotera Health during the 1st quarter valued at about $79,126,000. Sculptor Capital LP purchased a new position in shares of Sotera Health during the 4th quarter valued at about $68,400,000. Two Seas Capital LP raised its holdings in shares of Sotera Health by 624.0% during the 4th quarter. Two Seas Capital LP now owns 2,896,136 shares of the company’s stock valued at $39,619,000 after buying an additional 2,496,136 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in Sotera Health by 140.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,624,750 shares of the company’s stock worth $35,907,000 after purchasing an additional 1,534,666 shares during the period. Finally, Ananym Capital Management LP purchased a new position in Sotera Health in the 4th quarter worth approximately $13,680,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.